PubMed Health⌕ Search

PubMed · 15212750

Carbohydrate intake during exercise and performance.

Abstract

It is generally accepted that carbohydrate (CHO) feeding during exercise can improve endurance capacity (time to exhaustion) and exercise performance during prolonged exercise (>2 h). More recently, studies have also shown ergogenic effects of CHO feeding during shorter exercise of high intensity ( approximately 1 h at >75% of maximum oxygen consumption). During prolonged exercise the mechanism behind this performance improvement is likely to be related to maintenance of high rates of CHO oxidation and the prevention of hypoglycemia. Nevertheless, other mechanisms may play a role, depending on the type of exercise and the specific conditions. The mechanism for performance improvements during higher-intensity exercise is less clear, but there is some evidence that CHO can have central effects. In the past few years, studies have investigated ways to optimize CHO delivery and bioavailability. An analysis of all studies available shows that a single CHO ingested during exercise will be oxidized at rates up to about 1 g/min, even when large amounts of CHO are ingested. Combinations of CHO that use different intestinal transporters for absorption (e.g., glucose and fructose) have been shown to result in higher oxidation rates, and this seems to be a way to increase exogenous CHO oxidation rates by 20% to 50%. The search will continue for ways to further improve CHO delivery and to improve the oxidation efficiency resulting in less accumulation of CHO in the gastrointestinal tract and potentially decreasing gastrointestinal problems during prolonged exercise.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Asker E Jeukendrup. Carbohydrate intake during exercise and performance.. https://doi.org/10.1016/j.nut.2004.04.017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Curvature-adjusted optimal design of sampling times for the inference of pharmacokinetic compartment models.

In pharmacokinetics, compartment models are often used to describe the time course of blood concentration after the administration of a drug. In this article, we propose an optimal design criterion for precise estimation of parameters included in the compartment model and illustrate the non-sequential design of sampling times of blood drug concentration data in individual pharmacokinetics. The proposed optimal design criterion minimizes the determinant of the mean-squared error matrix of the parameter estimator that is quadratically approximated by the curvature array. Therefore, the proposed criterion considers the intrinsic and parameter-effects nonlinearity underlying the compartment model, and so is applicable in a pharmacokinetic experiment where the sample size of the blood drug concentration data is quite small.

Biological Availability↗

Biowaiver monographs for immediate release solid oral dosage forms: isoniazid.

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical ingredient (API) are reviewed. Isoniazid's solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), as well as its therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. Isoniazid is "highly soluble" but data on its oral absorption and permeability are inconclusive, suggesting this API to be on the borderline of BCS Class I and III. For a number of excipients, an interaction with the permeability is extreme unlikely, but lactose and other deoxidizing saccharides can form condensation products with isoniazid, which may be less permeable than the free API. A biowaiver is recommended for IR solid oral drug products containing isoniazid as the sole API, provided that the test product meets the WHO requirements for "very rapidly dissolving" and contains only the excipients commonly used in isoniazid products, as listed in this article. Lactose and/or other deoxidizing saccharides containing formulations should be subjected to an in vivo BE study.

Biological Availability↗

Experimental approaches for studying uptake and action of herbal medicines.

In order to gain wider credibility, herbal medicines must go through the rigorous scientific scrutiny to which synthetic drugs are subjected, and this includes investigating their absorption, bioavailability and metabolism. This review describes approaches for determining how active compounds in herbal formulations enter the systemic circulation. To assess how bioactive molecules enter the target organs and cells, specific cell lines and organ culture models can be used, followed by in vitro models to show how they may regulate digestion, energy balance and metabolism. This could lead to a better understanding of how herbal medicines affect digestion and absorption; fundamental questions which should be answered in addition to their mechanism of action.

Biological Availability↗